Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madlen Jüttner

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Plos One|September 17, 2014
Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibodyNikolai Siebert, Diana Seidel, Christin Eger, et al.
Journal of Immunological Methods|April 15, 2014
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHONikolai Siebert, Christin Eger, Diana Seidel, et al.
Oncoimmunology|November 11, 2017
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD<sub>2</sub> antibody ch14.18/CHONikolai Siebert, Maxi Zumpe, Madlen Jüttner, et al.
Prostaglandins & Other Lipid Mediators|November 25, 2010
PGE1 and PGE2 modify platelet function through different prostanoid receptorsDavid Iyú, Madlen Jüttner, Jackie R Glenn, et al.
Plos One|March 12, 2016
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against NeuroblastomaChristin Eger, Nikolai Siebert, Diana Seidel, et al.
Oncoimmunology|December 22, 2016
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalNikolai Siebert, Christian Jensen, Sascha Troschke-Meurer, et al.
Mabs|January 21, 2016
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2Nikolai Siebert, Christin Eger, Diana Seidel, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Plos One|September 17, 2014
Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibodyNikolai Siebert, Diana Seidel, Christin Eger, et al.
Journal of Immunological Methods|April 15, 2014
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHONikolai Siebert, Christin Eger, Diana Seidel, et al.
Oncoimmunology|November 11, 2017
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD<sub>2</sub> antibody ch14.18/CHONikolai Siebert, Maxi Zumpe, Madlen Jüttner, et al.
Prostaglandins & Other Lipid Mediators|November 25, 2010
PGE1 and PGE2 modify platelet function through different prostanoid receptorsDavid Iyú, Madlen Jüttner, Jackie R Glenn, et al.
Plos One|March 12, 2016
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against NeuroblastomaChristin Eger, Nikolai Siebert, Diana Seidel, et al.
Oncoimmunology|December 22, 2016
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalNikolai Siebert, Christian Jensen, Sascha Troschke-Meurer, et al.
Mabs|January 21, 2016
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2Nikolai Siebert, Christin Eger, Diana Seidel, et al.
Pageof 1